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Abst rac t
Introduction: The only etiological and decisive therapy, able to influence the natural history of latex allergy is the 
specific desensitization.
Aim: To verify the clinical efficacy and immunological changes determined by latex sublingual immunotherapy in 
allergic patients who underwent this treatment for at least 3 years.
Material and methods: We enrolled 76 patients (16 males and 60 females, mean age 34 years old) with evidence 
of a natural rubber latex allergy. To assess the effectiveness of the immunotherapy we performed a latex skin prick 
test, specific IgE and IgG4 and challenge tests before and after at least 3 years of desensitization.
Results: We observed a reduction in the mean diameter of the wheal area at the skin prick test and a decrease in 
latex specific IgE while no significant changes of latex IgG4 values were found. Moreover a reduction of symptoms 
and scores at the provocation tests were remarked.
Conclusions: Although the primary prevention (which still remains the gold standard treatment for patients suf-
fering from the latex allergy) sublingual immunotherapy can be offered with efficacy in addition to symptomatic 
treatment to selected patients. 
Key words: latex allergy, sublingual immunotherapy, challenge, desensitization.
Introduction
Allergic reactions to natural rubber latex (NRL) have 
been reported since 1970 and during the last decades 
they became an emerging clinical problem of public 
health. Symptoms of a NRL allergy range from contact 
urticaria and asthma to anaphylaxis and they are elicited 
by direct contact with NRL items (i.e. medical devices) or 
by inhalation of latex airborne proteins. 
The prevalence rates of sensitization in pediatric and 
adult population are 0.3% and 0.7%, respectively [1]. The 
latex allergy mostly affects certain groups of population 
with a high risk of sensitization (healthcare workers, pa-
tients with frequent hospitalization, etc.) and recently 
there has been an increasing number of cases of the 
NRL allergy in other occupations such as hairdressers, 
housekeepers, security personnel, etc. [2], probably due 
to widespread exposure to latex gloves. 
The diagnosis of the latex allergy is formulated on 
the basis of personal history and on an accurate allergo-
logical evaluation; the patients with a history of adverse 
reactions during medical or surgical procedures, food 
intolerance or risk factors should undergo a latex skin 
prick test (SPT), latex specific IgE (sIgE) assay and chal-
lenge tests (nasal, conjunctival, bronchial, intravaginal, 
sublingual, cutaneous).
Proper diagnosis of the latex allergy is important for 
appropriate preventive measures and treatment [3].
In fact, the progressive corrective measures adopted, 
including the substitution of NRL with other materials 
or the use of powder-free gloves, resulted in a decline in 
incidence of this disease [4].
Actually the complete avoidance of NRL is recom-
mended to reduce the risk of symptoms onset in allergic 
patients; however, in some subjects this measure is not 
sufficient and it is complicated by the ubiquity of latex 
products and by the cross-reactions to latex and fruit/
vegetables (latex-fruit syndrome).
The only etiological and decisive therapy, able to in-
fluence the natural history of latex allergy is the specific 
desensitization. Only few studies have been published 
regarding its efficacy and tolerance. 
Advances in Dermatology and Allergology 2, April / 2018146
E. Nucera, S. Mezzacappa, A. Buonomo, M. Centrone, A. Rizzi, P.F. Manicone, G. Patriarca, A. Aruanno, D. Schiavino
Our previous study [5] showed an improvement in 
skin and respiratory symptoms and in conjunctival chal-
lenge tests after the desensitization. At the end of the 
therapy, in fact, almost all patients were able to wear 
latex gloves, to undergo medical or surgical interven-
tion, to stay in environments where latex is present. Our 
protocol of rush latex desensitization treatment (Table 1) 
was performed in 4 days, during which increasing dos-
es of the latex extract (Alk-Abellò, Milan) were admin-
istered under the patient’s tongue until reaching the 
highest dose of 500 µg of latex during hospitalization. 
A maintenance therapy (10 drops of an undiluted solu-
tion three times a week) was followed at home. All the 
patients were equipped with an emergency kit which 
included auto injectable epinephrine, betamethasone 
and clorphenamine and we suggested future specialist 
visits in latex-safe environment before latex tolerance 
was acquired.
In another open-label and non-controlled study, Cis-
tero [6], in a trial of 10 weeks, demonstrated a higher 
tolerability of the sublingual than subcutaneous route. 
In a double-blind, placebo-controlled study of 1-year sub-
lingual immunotherapy, Nettis [7] showed a significant 
improvement in symptoms and medication scores after 
the 12 months’ treatment. Finally, another trial suggested 
that latex sublingual immunotherapy (SLIT) was more ef-
fective than placebo after 1-year follow-up, but only 9 pa-
tients completed the study and, hence, results must be 
treated with caution [8].
All these studies described in literature have some 
deficiencies (an inappropriate trial design, short follow-
up or the use of different commercial products). Thus, 
given that we decided to verify the clinical efficacy and 
immunological changes determined by NRL immunother-
apy in allergic patients who underwent this treatment 
for at least 3 years, as happened in respiratory immuno-
therapy [9, 10] and food allergy [11].
Material and methods 
Trial design
This study is an observational trial and its aim is to 
verify the clinical efficacy of NRL SLIT (Alk-abellò) in pa-
tients who finished the treatment or were treated for at 
least 3 years.
The primary endpoint was assessed by the changes 
in the response to challenge tests (cutaneous, mucous-
oral, conjunctival, nasal), performed before and after 
3 years of therapy.
The secondary endpoint was to evaluate the possible 
immunological changes determined by the immunother-
apy by means of skin prick tests with latex (Alk-abellò, 
Milan), and the assay of latex specific IgE and IgG4.
Patients
The study was carried out on all the subjects referred 
to the Allergy Department of Policlinico “A. Gemelli” 
in Rome with evidence of an NRL allergy (positive SPT 
and specific IgE). The diagnosis of the latex allergy was 
confirmed by challenge tests (cutaneous, mucous-oral, 
nasal, and conjunctival). All subjects were questioned 
about symptoms after latex exposure (ranging from con-
tact urticaria to anaphylaxis) and possible risk factors 
(atopy; occupation as healthcare workers, dentists, rub-
ber plantation workers, etc.; multiple surgical operations; 
myelomeningocele). 
The inclusion criteria were: age 18–60 years, an im-
mediate reaction after latex exposure, positive skin prick 
test for latex (Alk-abellò) (> 3 mm), positive latex specific 
IgE assay (> 0.35 KU/l) (Phadia, Uppsala, Sweden) and 
positive latex challenge.
The exclusion criteria were ongoing breastfeeding or 
pregnancy, positive placebo challenge and any clinical 
condition that contraindicates immunotherapy accord-
ing to the European Academy of Allergy and Clinical Im-
munology (EAACI) guidelines [12]. 
Written informed consent was obtained from all pa-
tients.
Every patient signed informed consent to perform 
challenge tests and subsequently to undergo the desen-
sitization treatment.
Skin prick test
All patients underwent the skin prick test (SPT) with 
the NRL extract (Alk-Abellò, Milan, Italy). All SPT were 
performed and read after 15 min according to the EAACI 
guidelines [13]: a wheal diameter greater than or equal to 
3 mm was considered as a positive result. Skin prick test 
with a histamine (10 mg/ml) and saline solution were 
carried out as positive and negative controls, respectively. 
Table 1. Rush sublingual desensitization treatmnent to latex
Day Concentration Administered dose Total dose
1 From 10–18 to 10–10 1 drop every administration 28 per 10–10 µg of NRL
2 From 10–9 to 10–1 1 drop every administration 2.8 µg of NRL
3 Undiluted solution (500 µg/ml) 1, 2, 3, 4, 5, 10 drops 500 µg of NRL
Maintenance treatment: 10 drops 3 times a week.
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In vitro parameters 
Serum samples were collected before and after the 
treatment for the assay of latex specific IgE and IgG4 by 
the UniCAP System (Thermo-fisher); samples with spe-
cific IgE concentrations of ≥ 0.35 KU/l were considered 
as positive. 
Challenge tests [14]
Latex provocation tests were performed in a day 
hospital regimen under physician observation and vital 
parameters were monitored during each test.
The cutaneous provocation test consisted of wearing 
a latex glove (Triflex Allegiance Health Care Co., McGaw 
Park, IL, USA) on one hand for 60 min. 
The mucous-oral challenges were carried out by ask-
ing the patient to hold a latex-gloved test tube in the 
mouth until symptoms appeared or up to 1 h.
The conjunctival and nasal challenges were per-
formed by instilling latex into the inferior fornix of alter-
nate eyes or by inhaling latex solutions of the commer-
cial extract, starting with the concentration of 500 × 10–8 
µg/ml up to 50 µg/ml.
During latex challenge tests, ocular (tearing, itching, 
erythema and conjunctival edema), respiratory (rhinor-
rhea, nasal itching, nasal blockage, sneezing, wheezing, 
cough, dyspnea and laryngospasm) and muco-cutaneous 
symptoms (generalized pruritus, erythematous-papular 
rash, urticarial-angioedema, oral and pharyngeal itching) 
were recorded by the same physicians who observed the 
patient until the end of each challenge and assessed 
score symptoms on a four-point scale: 0 (absent), 
1 (mild), 2 (moderate) and 3 (severe). Also a medication 
score, assessing administration of symptomatic medica-
tion during these provocation tests, was calculated ac-
cordingly to each therapeutic category: 1 point for local 
anti-allergic treatment, 2 points for an antihistamine 
tablet and 3 points for parenteral therapy (steroids or 
antihistamines).
Immunotherapy schedule 
A rush sublingual desensitizing treatment with latex 
was performed in 4 days by administering increasing 
doses of the latex extract under the patients’ tongue [8]. 
The patients were instructed to keep the allergen solu-
tion in the mouth for at least 3 min and then swallow 
it. The protocol started with a drop of the latex solution 
(500 µg/ml) diluted 1 : 1018 until reaching the highest 
dose of 1 ml of the undiluted solution (500 µg of latex). 
A maintenance therapy (500 µg of undiluted solution 
three times a week) was recommended (Table 1).
All patients were equipped with a diary, where they 
were asked to indicate possible side effects relating to 
SLIT, an emergency kit (antihistamines, corticosteroids, 
auto injectable epinephrine) to manage adverse reac-
tions and we suggested future specialist visits in latex-
safe environment. 
The treatment started in a Day Hospital regimen and, 
when the patients reached the maintenance dose, con-
tinued at home with monthly hospital visits to hand back 
the diary to monitor the compliance. 
Statistical analysis
We performed the McNemar’s c2 test and the Wil-
coxon-Mann-Whitney test to evaluate the results of the 
challenges and the changes in skin prick tests, latex spe-
cific IgE and IgG4 before and after the desensitization. 
The significance level was set at p > 0.05. 
Results
We enrolled 76 patients (16 males and 60 females, 
mean age 34 years old) with evidence of the NRL allergy 
who underwent desensitization treatment for at least 
3 years.
At time of diagnosis, all but two patients were posi-
tive to the skin prick test with latex and 67 out of the 
76 subjects presented positive latex specific IgE. These 
patients fulfilled inclusion criteria because the latex al-
lergy diagnosis was confirmed by challenge tests.
After the desensitization treatment, we observed 
a negative latex SPT only in 9 patients but in 91% of our 
population we observed a decrease in the mean diam-
eter of the wheal area from 7.78 mm before the SLIT to 
5.24 mm after SLIT (p < 0.001) (Figure 1).
Considering serum levels of latex specific IgE after 
desensitization we detected a value < 0.35 kU/l in 10 pa-
tients although a reduction in this value was measured 
in 78% of patients (the mean value of specific IgE was 
13.33 KU/l before the SLIT and 8.95 kU/l after the SLIT, 
p < 0.01) (Figure 2).
The values of specific IgG4 did not show significant 
changes after desensitization.
The results of challenges are presented in Table 2.
Figure 1. Latex SPT before and after sublingual immuno-
therapy (ITS)
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At the beginning of the study, a cutaneous provoca-
tion test was carried out in 72 out of 76 patients because 
the remaining 4 patients presented dermatitis of their 
hands. During the test, 57 subjects developed adverse 
reactions (rhinoconjunctivitis, cutaneous symptoms or 
both); of these subjects 48 became negative at the end 
of the trial (p < 0.01). Anyway, regarding the other 9/57 
patients who remained positive at the cutaneous test, 
no changes were observed in the total symptoms score 
before and after the SLIT.
The other challenges (mucous-oral, conjunctival and 
nasal) have been performed in a limited number of pa-
tients because not all the subjects gave their consent to 
undergo the procedures.
The mucous challenge test, performed in 45 out of 
76 subjects, scored positive in 11 of them; after the im-
munotherapy 4 patients still reacted but there was 
a slight decrease in the total symptoms score that cut 
down from 13 to 10 (p = 0.003).
Before the treatment, the nasal provocation test was 
performed in 26 out of 76 patients and 24 subjects were 
positive: after 10–45 min, they presented rhinoconjunc-
tivitis or cutaneous symptoms. After 3 years of immuno-
therapy only 5 out of 24 patients were still positive but 
we observed a slight reduction in total symptoms score 
from a value of 13 to 8 but this result, although interest-
ing, was not statistically significant.
Concerning 46 out of 76 patients who performed the 
conjunctival test, we observed a clear negativity in 15 out 
of 42 subjects who had an adverse reaction during this 
test before the treatment (p < 0.05). In patients who were 
still positive to this challenge after the desensitization 
there was a decrease in the total symptoms score from 
71 to 50.
During the trial, 35/76 patients came into contact ac-
cidentally with latex: 25 of them did not present an ad-
verse reaction, while 10/35 developed an allergic reaction 
which consisted of mild cutaneous symptoms in all cases 
and one patient had a systemic reaction.
Discussion
The main therapeutic approach in latex sensitized 
subjects is to avoid latex exposure. In patients that have 
difficulties in applying adequate avoidance measures, 
a sublingual immunotherapy is recommended.
Our team has already widely published on this mat-
ter.
Table 2. Results of challenge tests
Variable Positive before immunotherapy Positive after immunotherapy
Latex skin prick test (n = 76) 74 65
Latex sIgE (n = 76) 67 57
Cutaneous challenge test (n = 72) 57 9
Mucous challenge test (n = 45) 11 (TSS = 13) 4 (TSS = 10)
Nasal challenge test (n = 26) 24 (TSS = 13) 5 (TSS = 8)
Conjuctival challenge test (n = 46) 42 (TSS = 71) 27 (TSS = 50)
TSS – total symptoms score.
Figure 2. Latex specific IgE before and after sublingual immunotherapy (ITS)
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In a publication of 2002 [4], we evaluated the efficacy 
of latex immunotherapy; we randomly assigned 12 pa-
tients as controls and 12 patients undergoing treatment 
according to the rush protocol. All patients performed 
cutaneous, mucosal, sublingual and conjunctival chal-
lenges, evaluating a symptoms score (baseline and after 
3 months). In the active group, we observed a significant 
reduction in latex specific IgE values in 7 patients and 
a negative outcome in cutaneous, mucosal and sublin-
gual challenges, while the conjunctival one showed only 
a significant symptoms score reduction. In conclusion, 
this study showed how the latex immunotherapy in 
4-day rush protocol is effective in patients with a latex 
allergy.
In a further experience [15], our team compared 2 dif-
ferent induction rush protocols (2 and 3 days) in terms of 
efficacy, safety and tolerability in reaching the mainte-
nance dose. The patients were randomized: 10 in group 
1 (2 days) and 12 in group 2 (3 days). The skin prick test 
became negative in 16 patients (8 in both group 1 and 2) 
and the remaining patients showed a significant symp-
toms score reduction. 
Other authors support the safety and efficacy of im-
munotherapy (SLIT) for latex.
Buyukozturk et al. [8] demonstrated a clear efficacy 
of desensitisation after 12 months’ treatment showing 
a reduction of symptoms and scores at the cutaneous 
provocation tests performed in allergic patients (all 
health professionals who were unable to prevent the 
clinical manifestations with the prevention procedures 
only). The same results were obtained by Bernardini 
et al. [16].
Lasa Luaces [17] showed both the effectiveness (in-
creased triggering dose during the conjunctival provo-
cation test) and immunological changes after 6 and 
12 months of treatment. In his work the IgG4 appeared to 
increase between 6 and 12 months of therapy, while the 
basophil activation test with latex showed a reduction of 
reactivity after 6 months. The IgE instead did not show 
statically significant variations.
Cisterò Bahima et al. [18] sought to evaluate the tol-
erability of SLIT latex and its effects on skin reactivity. 
Twenty-six allergic patients (history of skin and respirato-
ry symptoms after latex contact) underwent SLIT (4 days 
of induction with 9 weeks of maintenance). The cutane-
ous challenge, the rubbing test and the SPT were carried 
out before, during and at the end of SLIT. The cutaneous 
provocation test was greatly improved both after 5 days 
and 10 weeks of treatment, while the rubbing test only 
after 10 weeks. No changes in the SPT were detected. 
On the other hand, in the literature there are also 
cases that show lack of efficacy of the treatment: Morfin 
Maciel et al. [19] described the case of a boy who pre-
sented anaphylaxis after inspection in the airport with 
latex gloves despite latex immunotherapy. Gastaminza 
et al. [20] showed that there is no significant statistical 
difference between the active and placebo group either 
in vivo or in vitro. Moreover this group highlighted a re-
duction in the percentage of basophil activation both in 
the active group after 2 years of therapy and in the pla-
cebo group after 1 year of treatment.
The aim of our study was to update the data of the 
literature about the management of the latex allergy in 
those patients in whom the avoidance measures were 
not feasible or effective. The patients underwent latex 
SLIT for at least 3 years during which we checked the 
clinical and immunological changes comparing the out-
comes of the provocation test, skin prick test and in vitro 
test. 
Although in our study there was no control group, it 
must be highlighted that we enrolled a larger group of 
patients than the studies described above. 
In contrast with the observations of Lasa Luaces, in 
this work we observed a decrease in latex specific IgE 
as previously stated [4, 8] and no statistically significant 
changes of latex IgG4 values were found. On the other 
hand, we did not confirm the data of Cisterò Bahima, 
detecting a significant reduction in the mean diameter 
of the wheal area at SPT.
According to Cisterò Bahima, Buyukoturk, Bernardini 
and Lasa Luaces, a reduction of symptoms and scores at 
the provocation tests were remarked.
Conclusions
Although the primary prevention (and thus the com-
plete elimination of latex contact) still remains the gold 
standard treatment for patients suffering from the latex 
allergy, SLIT can be offered with efficacy in addition to 
symptomatic treatment to selected patients. 
For these reasons, further investigations in this field 
are needed, especially in order to identify tolerability, 
safety, long-term effectiveness and maintenance dos-
age, as the literature shows they are still widely variable.
Conflict of interest 
The authors declare no conflict of interest.
References
1. Niggemann B. IgE-mediated latex allergy – an exciting and 
instructive piece of allergy history. Pediatr Allergy Immunol 
2010; 21: 997-1001.
2. Rolland JM, O’Hehir RE. Latex allergy: a model for therapy. 
Clin Exp Allergy 2008; 38: 898-912. 
3. Chełmińska M, Specjalski K, Różyło A, et al. Differentiating 
of cross-reactions in patients with latex allergy with the use 
of ISAC test. Adv Dermatol Allergol 2016; 33: 120-7.
4. Allmers H, Schmengler J, John SM. Decreasing incidence of 
occupational urticaria caused by natural rubber latex allergy 
in German health care workers. J Allergy Immunol 2004; 114: 
347-51.
Advances in Dermatology and Allergology 2, April / 2018150
E. Nucera, S. Mezzacappa, A. Buonomo, M. Centrone, A. Rizzi, P.F. Manicone, G. Patriarca, A. Aruanno, D. Schiavino
5. Patriarca G, Nucera E, Pollastrini E, et al. Sublingual desen-
sitization: a new approach to latex allergy problem. Anesth 
Analg 2002; 95: 956-60.
6. Cistero Bahima A, Sastre J, Enrique E, et al. Tolerance and 
effects on skin reactivity to latex of sublingual rush immuno-
therapy with a latex extract. J Investig Allergol Clin Immunol 
2004; 14: 17-25.
7. Nettis E, Colanardi MC, Soccio Al, et al. Double-blind, pla-
cebo-controlled study of sublingual immunotherapy in pa-
tients with latex-induced urticaria: a 12-month study. Br 
J Dermatol 2007; 156: 674-81.
8. Buyukozturk S, Gelincik A, Özseker F, et al. Latex sublingual 
immunotherapy: can its safety be predicted. Ann Allergy 
Asthma Immunol 2010; 104: 339-42.
9. Durham SR, Emminger W, Kapp A, et al. Long-term clinical 
efficacy in grass pollen-induced rhinoconjunctivitis after 
treatment with SQ-standardized grass allergy immunother-
apy tablet. J Allergy Clin Immunol 2010; 125: 131-8.
10. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and 
immunologic effects of long-term sublingual immunothera-
py in asthmatic children sensitized to mites: a double-blind, 
placebo-controlled study. Allergy 2000; 55: 842-9.
11. Patriarca G, Schiavino D, Pecora V, et al. Food allergy and 
food intolerance: diagnosis and treatment. Intern Emerg 
Med 2009; 4: 11-24.
12. Malling HJ, Weeke B. Immunotherapy. Position paper of 
EAACI. Allergy 1993; 48 (Suppl. 14): 9-35.
13. Dreborg S, Frew A. Allergen standardization and skin tests. 
Allergy 1993; 48: 49-75.
14. Nucera E, Pollastrini E, Sabato V, et al. Challenge tests in 
the diagnosis of latex allergy. Int J Immunopathol Pharmacol 
2010; 23: 543-52.
15. Nucera E, Schiavino D, Sabato V, et al. Sublingual immuno-
therapy for latex allergy: tolerability and safety profile of 
rush build-up phase. Curr Med Res Opin 2008; 24: 1147-54.
16. Bernardini R, Pecora S, Milani M, Burastero SE. Natural rub-
ber latex allergy in children: clinical and immunological ef-
fects of 3-years sublingual immunotherapy. Eur Ann Allergy 
Clin Immunol 2008; 40: 142-7.
17. Lasa Luaces EM, Tabar Purroy AI, García Figueroa BE, et al. 
Component-resolved immunologic modifications, efficacy, 
and tolerance of latex sublingual immunotherapy in chil-
dren. Ann Allergy Asthma Immunol 2012; 108: 367-72. 
18. Cisterò Bahima A, Sastre J, Enrique E, et al. Tolerance and 
effects on skin reactivity to latex of sublingual rush immuno-
therapy with a latex extract. J Investig Allergol Clin Immunol 
2004; 14: 17-25.
19. Morfin Maciel BM, Castillo Morfin BM. Failure of sublingual 
immunotherapy to treat latex allergy. A report of a case. Rev 
Alerg Mex 2008; 55: 76-81. 
20. Gastaminza G, Algorta J, Uriel O, et al. Randomized, double-
blind, placebo-controled clinical trial of sublingual immuno-
therapy in natural rubber latex allergic patients. Trials 2011; 
12: 191.
